Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD5718 IR tablet
AZD5718 IR · 1 trial · 1 indication
Assessment of AUC of rosuvastatin when administered alone and in combination with AZD5718 in healthy volunteers.
Assessment of AUC(0-last) of rosuvastatin when administered alone and in combination with AZD5718 in healthy volunteers.
Assessment of Cmax of rosuvastatin when administered alone and in combination with AZD5718 in healthy volunteers.
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | 10 mg rosuvastatin tablet alone (fasting state) |
| Treatment B | EXPERIMENTAL | 10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state) |
| Treatment C | EXPERIMENTAL | 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state) |
| Treatment D | EXPERIMENTAL | 200 mg of AZD5718 oral suspension 50 mg/mL (fasting state) |
| Treatment E | EXPERIMENTAL | 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state) |
| Name | Type | Description |
|---|---|---|
| AZD5718 IR tablet | DRUG | - |
| AZD5718 oral suspension | DRUG | - |
| Rosuvastatin tablet | DRUG | - |
Inclusion Criteria: For inclusion in the study, subjects should fulfill the following criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Healthy male and/or female subjects (of non childbearing potential) aged 18 to 50 years (inclusive) ...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Viatris, Inc. | VTRS | 2 | PHASE3 | Selatogrel |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
AZD5718 IR is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for high risk coronary artery disease. The IR designation refers to an immediate release tablet formulation. It is in Phase 1 clinical development and has been studied in a single completed trial conducted in the United Kingdom.
AZD5718 IR is being developed for high risk coronary artery disease, a cardiovascular condition. The only completed clinical trial of AZD5718 IR enrolled healthy volunteers rather than patients with the disease, and it evaluated drug pharmacokinetics and relative bioavailability rather than clinical outcomes in coronary artery disease.
AZD5718 IR is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the Phase 1 trial of the immediate release tablet formulation conducted in the United Kingdom.
AZD5718 IR is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials of AZD5718 IR are currently active.
AZD5718 IR has been studied in one completed Phase 1 trial, NCT02963116, titled a study to estimate the effect of AZD5718 on the pharmacokinetics of rosuvastatin and to measure the relative bioavailability of AZD5718 oral suspension versus AZD5718 immediate release tablet. The trial enrolled 12 participants in the United Kingdom.
Yes, AZD5718 IR and AZD5718 IR tablet refer to the same asset. AZD5718 IR tablet is the immediate release tablet formulation of AZD5718, developed by AstraZeneca PLC. The completed Phase 1 trial NCT02963116 compared this immediate release tablet against an oral suspension formulation of AZD5718.